FDA Approves Castration-Sensitive Prostate Cancer Drug
February 9th 2018Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.
Read More